Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463390 | 1.00 | ALOX5 (0.58) | ALOX5MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL2570284 | 0.88 | CDC7 (0.61) | ALOX5MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL18639993 | 0.85 | MAOB (0.58) | MAPTKDM4EMAPK1NPSR1TDP1 | |
| SCHEMBL31704405 | 0.82 | FGFR1 (0.52) | MAPTKDM4EMAPK1NPSR1HSP90AA1 | |
| SCHEMBL16711152 | 0.78 | FGFR2 (0.71) | MAPTKDM4ETDP1CYP3A4FGFR1 | |
| SCHEMBL13923957 | 0.78 | FGFR1 (0.57) | MAPTKDM4EHSP90AA1FGFR1FGFR2 | |
| SCHEMBL16874309 | 0.77 | PTGER1 (0.51) | MAPTMAPK1TDP1CDC7MAOB | |
| SCHEMBL18441097 | 0.76 | CDC7 (0.60) | MAPTKDM4EMAPK1NPSR1HSP90AA1 | |
| SCHEMBL30025182 | 0.76 | PTPN7 (0.55) | MAPTKDM4EFGFR1FGFR2FGFR3 | |
| SCHEMBL19555316 | 0.76 | PTPN7 (0.55) | MAPTKDM4EFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223273-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2020-11-05 | — | — | WO | claimed |
| US-12465637-B2 | Compositions and methods for modulation of antibody activity | INSTITUTE FOR CANCER RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022197883-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | INSTITUTE FOR CANCER RESEARCH D/B/A (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220175918-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2022-06-09 | — | — | US | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3962926-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020223273-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20170342051-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-11-30 | — | — | US | disclosed |
| US-9765056-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-09-19 | — | — | US | disclosed |
| EP-3168217-A1 | NOVEL INDOLE AND PYRROLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2017-05-17 | — | — | EP | disclosed |
| EP-3027602-A1 | NOVEL DERIVATIVES OF INDOLE AND PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2015011396-A1 | NOVEL DERIVATIVES OF INDOLE AND PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2015-01-29 | — | — | WO | disclosed |
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2002098861-A1 | METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342051-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RB1, IDO1, BCL2A1 | ALOX5 871/4885MAPT 1338/4885KDM4E 2371/4885 |
| US-12465637-B2 | Compositions and methods for modulation of antibody activity | FCGR3B, FCGR2A, FCGRT | ALOX5 1198/4885MAPT 2906/4885KDM4E 3317/4885 |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, NFATC1 | ALOX5 436/4885MAPT 1975/4885KDM4E 1742/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | ALOX5 1340/4885MAPT 3301/4885KDM4E 2365/4885 |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | ALOX5 731/4885MAPT 2694/4885KDM4E 3909/4885 |
| US-20220175918-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY | FCGR3B, FCGR2A, FCGRT | ALOX5 1198/4885MAPT 2906/4885KDM4E 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.